Press 20/20 GeneSystems Enters Engagement Agreement with ClearingBid, Pioneer of the First “Crowd-Powered” Open IPOs 20/20 GeneSystems, Inc., an early market leader in multi-cancer early detection blood testing, announces that it has entered an Engagement Agreement with ClearingBid, Inc., a provider of the first platform enabling ordinary individuals and institutions to invest in IPOs at […]
The Future of Cancer Screening 20/20 GeneSystems pioneers innovative bio-testing and cancer diagnostic tools that address compelling unmet needs. 20/20’s digital diagnostics business develops and commercializes A.I. powered cancer screenings tests deliver better tools to improve early detection of the most common cancers globally. Our emergency bio-detection business includes our patented BioCheck which is widely used by emergency responders.
Welcome to 20/20 GeneSytems Read More »
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development.
